Navigation Links
Aethlon Medical Introduces HER2osome™, A Novel Therapeutic Device Strategy to Address Breast Cancer
Date:9/21/2011

iations for the BCRP from FY92 through FY10 totaled over $2.5 billion. The FY11 appropriation is $150 million.  Principal investigators underlying the Aethlon BCRP funding proposal are Dr. CS Chen, Chief, Division of Hematology and Oncology and Medical Director of the Loma Linda Cancer Center, and Dr. Douglas Taylor, Professor, Department of Obstetrics & Gynecology at University of Louisville School of Medicine.

The evolution of HER2osome™ therapy is based upon an adaptable dialysis-like affinity platform technology known as the Aethlon ADAPT™ system.  Therapies evolved from the Aethlon ADAPT™ system target the selective clearance of harmful agents from the entire blood volume within clinically relevant time frames and without the loss of essential blood components. Thus, overcoming the historic limitation of extracorporeal strategies that indiscriminately adsorb or remove particles solely by molecule size. In function, the device platform allows the immobilization of single or multiple affinity agents in the outer-capillary space of plasma filtration membrane technology as a means to provide rapid real-time clearance of corresponding targets.  In the case of HER2osome™, the immobilization of a HER2 antibody and an exosome targeted affinity agent provides a mechanism to clear both targets from the circulatory system of HER2+ breast cancer patients.  Like all ADAPT™ derived therapies, HER2osome™ will operate dialysate free, will not require replacement fluids, and can be utilized on dialysis machines or CRRT systems already located in hospitals and clinics worldwide.

Aethlon has previously leveraged its ADAPT™ system through a proposal chosen for funding through a DOD contract award under DARPA-BAA-11-30 entitled "Dialysis-Like Therapeutics".  The proposed program, which is pending completion of a contracting phase, would support the development of a therapeutic device that reduces
'/>"/>

SOURCE Aethlon Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Aethlon Medical to Present at the 2009 RedChip Small-Cap Investor Conference on June 16, 2009
2. Aethlon Medical Announces Presentation of Hepatitis-C (HCV) Clinical Data at 42nd Annual American Society of Nephrology (ASN) Conference
3. Aethlon Medical Releases Medical Device Data Against the H1N1 Swine Flu Virus
4. Aethlon Medical Discloses Live Webcast of Todays BIOCOM Presentation
5. Aethlon Medical Announces Expansion of Hepatitis C Virus (HCV) Treatment Programs
6. Aethlon Medical Announces Approval of Hepatitis C Virus (HCV) Treatment Program
7. Aethlon Medical to Present at Rodman & Renshaw Annual Global Investment Conference
8. Aethlon Medical Reestablishes Biodefense Programs
9. Aethlon Medical Engages Fabiani & Company to Advance U.S. Government Partnerships
10. Aethlon Medical Announces Appointment of Rod Kenley to Its Board of Directors
11. Aethlon Medical Names Rod Kenley President
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... LONDON and BOSTON , January ... structure-guided drug discovery and development company, is delighted to announce ... has been awarded to Miles Congreve (Vice President ... co-founder) and Malcolm Weir (Chief Executive Officer and ...
(Date:1/22/2015)... SAN DIEGO, Jan. 22, 2015  ResMed Inc. (NYSE: ... 31, 2014. Revenue for the quarter was $423.0 million, a ... 2013 (a 14 percent increase on a constant currency basis). ... compared to the quarter ended December 31, 2013. Diluted earnings ...
(Date:1/22/2015)... Increasing sophistication among enterprise buyers of language services ... 2015, says Moravia CMO, Renato Beninatto ... market research firm Common Sense Advisory, 15 percent of ... and localization needs. "From a language industry perspective, this ...
Breaking Medicine Technology:Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 2Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 11Moravia Sees Single-Sourcing as Key Localization Trend in 2015 2
... Lilly and Company (NYSE: LLY ) announced ... Lilly to access innovation being developed outside the company,s ... independent venture capital firms participating in the Mirror Portfolio ... stage of their development. The first is a molecule ...
... 2011 Mylan Inc. (Nasdaq: MYL ) ... launched Voriconazole Tablets, 50 mg and 200 mg, under ... Inc. Mylan was the first company to have filed ... for Voriconazole Tablets and was awarded 180 days of ...
Cached Medicine Technology:Lilly Marks Major Milestone for Mirror Portfolio with Agreement by Independent Fund to License First Two Investigational Medicines 2Lilly Marks Major Milestone for Mirror Portfolio with Agreement by Independent Fund to License First Two Investigational Medicines 3Lilly Marks Major Milestone for Mirror Portfolio with Agreement by Independent Fund to License First Two Investigational Medicines 4
(Date:1/22/2015)... Gabe’s Chemo Duck Program is pleased to announce the release ... for kids with cancer. The Chemo Duck App, available on iTunes ... enjoyable games to help children of all ages living with cancer ... keep kids entertained, educated and at ease while waiting for clinic ...
(Date:1/22/2015)... 2015 Blue Cross and Blue Shield of ... what it means to “Live Fearless.” , The ... share their stories about how they or someone they know ... by living in the moment. By telling these types of ...
(Date:1/22/2015)... 2015 Thousand of GranuFlo lawsuits ( ... its GranuFlo and NaturaLyte dialysis concentrates continue to move ... District Court, District of Massachusetts, Bernstein Liebhard LLP reports. ... has remanded a case filed by the state of ...
(Date:1/22/2015)... NY (PRWEB) January 22, 2015 ... of Sports Medicine flagship journal Medicine & Science ... L-Citrulline before exercise may help reduce gastrointestinal (GI) ... 1 , Participants in the double-blind, placebo-controlled ...
(Date:1/22/2015)... WASHINGTON, DC (PRWEB) January 22, 2015 ... conditions in vulnerable communities and cause financial distress to ... report by analysts at Howard University’s Center on Race ... of dollars in economic activity, payday loans at the ...
Breaking Medicine News(10 mins):Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2
... DURHAM, N.C., Sept. 22 Oxygen Biotherapeutics, Inc. (OTC Bulletin ... present at an investor conferences in Zurich on Sept. 30, 2009. , ... Radisson Hotel and is scheduled for 7:00 p.m. The German language presentation ... , , About Oxygen Biotherapeutics, Inc. , ...
... WESTFORD, Mass., Sept. 22 Cynosure, Inc. (Nasdaq: ... array of light-based aesthetic treatment systems, today announced that President and ... will present at the third annual Maxim Group Growth Conference in ... will be webcast live over the Internet beginning at 10:00 a.m. ...
... transmitted infection rates, researchers say , TUESDAY, Sept. 22 ... wives are more likely to have a sexually transmitted ... new study has found. , The researchers behind ... the risk, noting the widowers might be seduced by ...
... SEATTLE, Sept. 22 Milliman, Inc., one of the premier worldwide ... new office in San Juan, Puerto Rico. The consultancy, in concert ... expanding the range and depth of Milliman health-related service offerings. , ... years of experience are ideally suited to meeting client needs in ...
... , , MOUNTAIN VIEW, ... devices for clot removal in ischemic stroke patients, today announced the ... catheters are a first-in-class family of devices used to provide distal ... other neurovascular procedures. , , The original ...
... , , , ... that it has received certification to the ISO 13485:2003 ... Surgical Adhesives. Receipt of the certification allows Cohera ... approval process for TissuGlu(R), the company,s novel internal surgical ...
Cached Medicine News:Health News:Cynosure to Present at the Maxim Group Growth Conference 2Health News:Sex With New Partners Raises Widowers' Disease Risk 2Health News:Milliman Announces the Opening of a New Office in San Juan, Puerto Rico 2Health News:Concentric Medical Launches Full Family of DAC(TM) Neurovascular Catheters 2Health News:Cohera Medical Receives ISO 13485 Certification: Company Meets International Standards for Design, Development and Manufacturing of Medical Devices 2